Ropeginterferon alfa-2b
Ropeginterferon alfa-2b, sold under the brand name Besremi, is a medication used to treat polycythemia vera without symptomatic splenomegaly (enlarged spleen).[1]
| Clinical data | |
|---|---|
| Trade names | Besremi |
| License data | |
| Drug class | Interferon |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
It was approved for medical use in the European Union in February 2019.[1]
References
- "Besremi EPAR". European Medicines Agency (EMA). 12 December 2018. Retrieved 28 September 2020.
External links
- "Ropeginterferon alfa-2b". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.